Source comparison
BPC-157 vs Cortisone: Direct Protocol Comparison
Primary Mechanism Glucocorticoid receptor binding → prostaglandin suppression → inflammation halt VEGF upregulation → angiogenesis + fibroblast migration → collagen synthesis Cortisone suppresses; BPC-157 rebuilds. Opposite pathways. Time to Symptom Relief 24–
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Glucocorticoid receptor binding → prostaglandin suppression → inflammation halt
- VEGF upregulation → angiogenesis + fibroblast migration → collagen synthesis
- Cortisone suppresses; BPC-157 rebuilds. Opposite pathways.
- Time to Symptom Relief
- 24–72 hours (pain reduction via inflammation block)
- 7–14 days (gradual as tissue remodels)
- Cortisone wins for acute pain; BPC-157 delays relief.
- Effect on Tissue Structure
- Collagen synthesis ↓30–50%, tensile strength declines with repeat use
- Collagen deposition ↑47% (animal models), vascularization improves
- Cortisone weakens tissue long-term; BPC-157 strengthens.
- Typical Dosing
- 20–80mg triamcinolone, 1–3 injections spaced 6–12 weeks
- 250–500mcg/day subcutaneous, 4–8 weeks (research protocols)
- Cortisone requires clinical administration; BPC-157 self-administered.
- Clinical Evidence Level
- Decades of RCTs, systematic reviews, FDA-approved for inflammation
- Preclinical only. Animal models, no Phase III human trials
- Cortisone is proven; BPC-157 is mechanistically sound but untested clinically.
- Long-Term Structural Risk
- Tendon rupture risk ↑, cartilage thinning, repeat injections contraindicated
- No documented structural harm in animal studies; human data absent
- Cortisone's risks are known; BPC-157's unknowns remain.